Oncology Clinical Trials in Africa: Emerging and Operational Issues

Odedina, Folakemi T.; Ginsburg, Ophira

doi:10.1200/go.20.00233

Cited by 9 publications

(7 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Researchers can leverage Phase III research to develop new or test existing behavioural theories or theoretically driven constructs and models for their strength to explain and account for health behaviours. Key considerations, for example, might include developing new models for addressing energy imbalance (physical inactivity, sedentary behaviours, poor diet and obesity); reducing alcohol and tobacco use; increasing acceptability, uptake and adherence to screening and vaccination behaviours (Klein et al, 2021); improving shared decision making and treatment behaviours; but most importantly increasing participation in clinical trials and health services research (Odedina et al, 2020; Odedina & Ginsburg, 2020). A recent study from Kenya is a good example to consider (Vermandere et al, 2016).…”

Section: Discussionmentioning

confidence: 99%

“…Individuals of African ancestry, particularly those residing in Africa, are currently under‐represented in cancer research globally (Odedina & Ginsburg, 2020); there is, however, an urgent need to reverse this trend. On the one hand, the African population bears a disproportionate burden of cancer than many world regions and is affected by cancer in forms that are more aggressive and challenging to diagnose or treat (O. Bamidele et al, 2018).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Behavioural oncology research in Africa: Lessons from the last two decades and key considerations moving forward

Ezenwankwo

Ogbodo

Alom

et al. 2021

European J Cancer Care

View full text Add to dashboard Cite

Objective To analyse the state of behavioural oncology research in Africa and outline key considerations for future research. Methods Five bibliographic databases were searched to identify original English‐language articles published between January 2000 and August 2020. The Behavioural Epidemiology Framework was applied to studies with data/findings from Africa to delineate their current state. Research gaps/opportunities available for behavioural oncology research in Africa were further highlighted. Results Two hundred eighty‐seven original research with findings from Africa has been published over the last two decades, with the highest contribution arising from Nigeria, Kenya, Ethiopia and South Africa. Cervical and breast cancers were the most widely investigated. Prominently studied behaviours relate to cancer screening, health literacy, lifestyle, and vaccination. Behavioural oncology literature in Africa is generally in Phases I and III and lacks in measurement studies (<2%) and studies that seek to evaluate behaviour change/health promotion interventions (<6%) or translate them into practice (13.2%). Conclusion Embracing new and progressive approaches, including methodological/analytical paradigms and implementation science is imperative to advance the frontiers of behavioural oncology research in Africa. This calls for a responsive research approach that can mobilise multidisciplinary/multilevel coalitions, ensuring a research structure that effectively integrates behavioural research and cancer prevention/control in the region.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Behavioural oncology research in Africa: Lessons from the last two decades and key considerations moving forward

Ezenwankwo

Ogbodo

Alom

et al. 2021

European J Cancer Care

View full text Add to dashboard Cite

show abstract

“…These efforts are supported by the WHO, which has a mandate to assist and support nations in the development of effective cancer treatment strategies within the context of their national cancer programs and encourages formal and substantive links between academic centers and their equivalents in the developing world. 16 We recommend that this WHO mandate to work collaboratively and establish institutional linkages be strengthened along with using African regional collaborative networks/structures (such as 18 in JCO Global Oncology. It remains unknown whether these are GCP-diligent sites.…”

Section: Accepted Onmentioning

confidence: 99%

“…However, many countries lack the presence of cancer trials and, together with the well-known phenomena of barriers to running trials, there is a clear mandate for strategic development of clinical trial sites in Africa. 18…”

Section: Accepted Onmentioning

confidence: 99%

Oncology Clinical Trials in Africa: Partnering for Quality

Shamley

Ezeani

Okoye

2021

JCO Global Oncology

View full text Add to dashboard Cite

Oncology clinical trials are requisite for testing the safety and effectiveness of promising treatments and deciphering new knowledge into concrete benefits for patients. They present opportunities to innovate promising, novel cancer remedies. A dearth of local evidence to guide cancer treatment in Africans is creating an increased interest in oncology clinical trials to improve patient care. This is primarily because of limitations in pathology, surgery, medical oncology, radiation, and palliation that are leading to worse cancer outcomes on the continent. Investment in oversight of Human Research Ethics committees and Medicines Regulatory Authorities in Africa has improved the potential for many countries to host clinical trials. However, the distribution of cancer trials remains poor across the continent, resulting in inadequate treatment options for patients with cancer. There are some initiatives aimed at developing research capacity to host trials in Africa. However, there is now a need to establish strategic partnerships whose aim should be to achieve harmonized, accredited Clinical Trials Units capable of running trials to meet Good Clinical Practice standards. This article discusses what has been achieved and proposes a model for quality oversight of Clinical Trials Units in Africa.

show abstract

“…Given the unique characteristics of MM in Africans, research efforts specially focused on local African populations are required to optimize prevention, diagnosis and treatment interventions [ 29 ]. In Kenya, such research should include studies on prevalence of pre-malignant conditions (MGUS, smouldering MM), frequency of biomarkers including cytogenetic and genomic abnormalities and mechanistic studies to determine the role of genomic biomarkers in progression to MM from pre-malignant states.…”

Section: Conference Proceedingsmentioning

confidence: 99%

Towards a unified approach for multiple myeloma care in Kenya - proceedings of the Inaugural Multiple Myeloma Congress

Lotodo¹,

Melly²,

Manyega³

et al. 2021

Pan Afr Med J

View full text Add to dashboard Cite

The rising burden of multiple myeloma in Kenya has not been met by a commensurate effort for control. Patients and practitioners struggle with unavailability and unaffordability of diagnostics, drugs and stem cell transplant leading to presentation at advanced stages and under-treatment with increased morbidities and mortality. A concerted effort among stakeholders is urgently needed to develop strategies for myeloma control. The scarcity of providers also carries grave consequences for Kenyan patients. The Academic Model Providing Access To Healthcare (AMPATH) multiple myeloma program organized the Inaugural Virtual Multiple Myeloma Congress to achieve both interactive specialist instruction and stakeholder engagement. Expert presenters and panellists from diverse disciplines were invited to offer in-depth presentations on myeloma care and case studies from panellists´ practice were used to contextualize learning points and form a basis for generating debate on the challenges facing providers and opportunities for care improvement. An audience of health professionals offering care to myeloma patients was invited. The underlying principle of recommendations developed during the congress was collaboration among in-country and international practitioners, researchers and policy experts from private and public sector. This partnership of stakeholders bears the potential of pooling scarce resources and for collective advocacy towards better patient care

show abstract

Oncology Clinical Trials in Africa: Emerging and Operational Issues

Cited by 9 publications

References 12 publications

Behavioural oncology research in Africa: Lessons from the last two decades and key considerations moving forward

Behavioural oncology research in Africa: Lessons from the last two decades and key considerations moving forward

Oncology Clinical Trials in Africa: Partnering for Quality

Towards a unified approach for multiple myeloma care in Kenya - proceedings of the Inaugural Multiple Myeloma Congress

Contact Info

Product

Resources

About